<DOC>
	<DOCNO>NCT01311882</DOCNO>
	<brief_summary>This study evaluate next-day residual effect MK-4305 highway drive performance healthy , non-elderly participant .</brief_summary>
	<brief_title>A Study Evaluate Next Day Effects MK-4305 Driving Performance ( MK-4305-035 AM1 )</brief_title>
	<detailed_description />
	<mesh_term>Suvorexant</mesh_term>
	<mesh_term>Zopiclone</mesh_term>
	<criteria>Female participant reproductive potential must agree use ( and/or partner use ) acceptable method birth control begin least 2 week prior administration first dose study drug throughout study Has body mass index ( BMI ) within range 18 30 kg/m^2 Possesses valid driver 's license 3 year least 5000 km/year average within last 3 year Is capable drive manual transmission vehicle willing drive highway Is judge good health Has regular sleep pattern Is visually impaired Has history persistent sleep abnormality Has neurological disease/cognitive impairment Has history cataplexy Is regular user sedativehypnotic agent Is allergic zopiclone Has travel across 3 time zone ( transmeridian travel ) last 2 week prior study start travel across 3 time zone throughout study duration Works night shift able avoid night shift work within 1 week treatment visit Is pregnant nursing Does qualify proficient driver accord drive instructor evaluation subject 's driving driving test practice session</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>